LEADER 03798nam 2200889z- 450 001 9910619468703321 005 20231214132947.0 010 $a3-0365-4600-6 035 $a(CKB)5670000000391587 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93174 035 $a(EXLCZ)995670000000391587 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNanoparticle-Macrophage Interactions$eImplications for Nanosafety and Nanomedicine 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (208 p.) 311 $a3-0365-4599-9 330 $aNanoparticles (NPs) offer unique properties for biomedical applications, leading to new nanomedicines. Recent examples of advanced nanoparticle-based nanomedicines are COVID-19 RNA vaccines. Regardless of the delivery route of the NPs into the body (intravenous or subcutaneous injection, oral, intranasal, etc.), NPs inevitably come into contact with immune cells, such as macrophages. Macrophages are phagocytizing cells that determine the fate and the lifetime of NPs in relevant biological fluids or tissues, which has consequences for both nanosafety and nanomedicine. The aim of this Special Issue is to cover recent advancements in our understanding of NP?macrophage interactions, with a focus on in vitro models for nanosafety and novel nanomedicine approaches that allow the modulation of the immunological profile of macrophages. The current Special Issue compiles nine papers: seven research articles and two review articles. The original articles include studies on the interaction of different nanomaterials, such as multi-walled carbon nanotubes (MWCNTs), amorphous silica, gold nanoparticles, lipid carriers, and microspheres, with macrophages in different scenarios. 517 $aNanoparticle-Macrophage Interactions 606 $aMedicine$2bicssc 610 $achronic wound 610 $adevice 610 $afoot ulcer 610 $ainflammation 610 $awound healing 610 $amacrophage 610 $ananomaterial 610 $ananoparticle 610 $adrug delivery 610 $aimmune system 610 $aanti-inflammatory 610 $ainnate immunity 610 $aosteoarthritis 610 $arifabutin 610 $ananostructured lipid carriers 610 $acell uptake 610 $aCaco-2 cells 610 $aoral administration 610 $aCrohn's disease 610 $ananomaterials 610 $amacrophages 610 $aclass A type 1 scavenger receptors 610 $acytotoxicity 610 $amacrophage-nanoparticle interaction 610 $amonocytes 610 $agold nanoparticles 610 $ain vitro models 610 $ainnate memory 610 $a2D cultures 610 $a3D cultures 610 $acarbon nanotube 610 $ascavenger receptor 610 $aphagocytosis 610 $aprotein corona 610 $abovine serum albumin 610 $asynthetic amorphous silica 610 $ain vitro testing 610 $aNR8383 alveolar macrophage 610 $aICP-MS analysis of cell bound SiO2 610 $amulti-walled carbon nanotubes 610 $ananoparticles 610 $achemokines 610 $atranscriptomics 610 $azebrafish 615 7$aMedicine 700 $aBondarenko$b Olesja$4edt$01309484 702 $aTorres Ando?n$b Fernando$4edt 702 $aBondarenko$b Olesja$4oth 702 $aTorres Ando?n$b Fernando$4oth 906 $aBOOK 912 $a9910619468703321 996 $aNanoparticle-Macrophage Interactions$93029367 997 $aUNINA